Replication data for: Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs

Principal Investigator(s):  View help for Principal Investigator(s) Margaret Kyle; Heidi Williams

Version:  View help for Version V1

Name File Type Size Last Modified
CIS.dta application/octet-stream 9 MB 10/12/2019 08:00:AM
CIS_HAS_ASMR.dta application/octet-stream 9.7 MB 10/12/2019 08:00:AM
CIS_HAS_SMR.dta application/octet-stream 16 MB 10/12/2019 08:00:AM
LICENSE.txt text/plain 14.6 KB 10/12/2019 08:00:AM
Product.dta application/octet-stream 18.2 MB 10/12/2019 08:00:AM
RegActionDate.dta application/octet-stream 4.1 MB 10/12/2019 08:00:AM
analysis.do text/plain 21.4 KB 10/12/2019 08:00:AM
application.dta application/octet-stream 1.4 MB 10/12/2019 08:00:AM
fda_ims_match_manual.xlsx application/vnd.openxmlformats-officedocument.spreadsheetml.sheet 619.8 KB 10/12/2019 08:00:AM
prepdata.do text/plain 16.2 KB 10/12/2019 08:00:AM

Project Citation: 

Kyle, Margaret, and Williams, Heidi. Replication data for: Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs. Nashville, TN: American Economic Association [publisher], 2017. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2019-10-12. https://doi.org/10.3886/E113519V1

Project Description

Summary:  View help for Summary Alan Garber and Jonathan Skinner (2008) famously conjectured that the US health care system was "uniquely inefficient" relative to other countries. We test this idea using cross-country data on prescription drug sales newly linked with an arguably objective measure of relative therapeutic benefits, or drug quality. Specifically, we investigate how higher and lower quality drugs diffuse in the US relative to Australia, Canada, Switzerland, and the UK. Our tabulations suggest that lower quality drugs diffuse more in the US relative to high quality drugs compared to each of our four comparison countries--consistent with Garber and Skinner's conjecture.

Scope of Project

JEL Classification:  View help for JEL Classification
      H51 National Government Expenditures and Health
      I11 Analysis of Health Care Markets
      I18 Health: Government Policy; Regulation; Public Health
      L65 Chemicals; Rubber; Drugs; Biotechnology; Plastics


Related Publications

Download this project

Published Versions

V1 [2019-10-12]

Export Metadata

Dublin Core

DDI 2.5

Report a Problem

Found a serious problem with the data, such as disclosure risk or copyrighted content? Let us know.

This material is distributed exactly as it arrived from the data depositor. ICPSR has not checked or processed this material. Users should consult the investigator(s) if further information is desired.